Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Crescita Therapeutics Inc (TSX: CTX )

0.5800 -0.0100 (-1.69%)
Streaming Delayed Price Updated: 12:38 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,217
Open 0.5900
Bid (Size) 0.5800 (35)
Ask (Size) 0.5900 (200)
Prev. Close 0.5900
Today's Range 0.5800 - 0.5900
52wk Range 0.3600 - 0.6900
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Crescita Therapeutics Announces Approval of Normal Course Issuer Bid
From Crescita Therapeutics
Via Business Wire
Keynotes and 50 Companies to Present at the Planet MicroCap Showcase: VANCOUVER in association with Small Cap Discoveries on September 25-26, 2024 at the Fairmont Waterfront Vancouver
Via ACCESSWIRE

Performance

YTD
+18.37%
+18.37%
1 Month
-3.33%
-3.33%
3 Month
-13.43%
-13.43%
6 Month
+33.33%
+33.33%
1 Year
-4.92%
-4.92%

More News

Read More
Crescita to Present & Participate in 1x1 Meetings at the Planet MicroCap Showcase: VANCOUVER 2024 in Association with Small Cap Discoveries on Thursday, September 26, 2024
From Crescita Therapeutics
Via Business Wire
Crescita Reports Second Quarter 2024 Results
From Crescita Therapeutics
Via Business Wire
Crescita Secures Contract Manufacturing Revenue of $US10 Million Over 4 Years
From Crescita Therapeutics
Via Business Wire
Leading Canadian Healthcare Services Provider Selects Crescita as Exclusive Manufacturing Partner under 5-Year Agreement
From Crescita Therapeutics
Via Business Wire
Crescita Expands Medical Aesthetic Portfolio with MicronJetTM600 The World’s Smallest Intradermal Delivery Device
From Crescita Therapeutics
Via Business Wire
Crescita Completes Acquisition of Strategic Assets of Occy Laboratory
From Crescita Therapeutics
Via Business Wire
Crescita to Acquire Strategic Assets of Occy Laboratory
From Crescita Therapeutics
Via Business Wire
Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders
From Crescita Therapeutics
Via Business Wire
Crescita Reports First Quarter 2024 Results
From Crescita Therapeutics
Via Business Wire
Crescita Reports Q4 and Fiscal 2023 Results
From Crescita Therapeutics
Via Business Wire
Crescita Reports Third Quarter 2023 Results
From Crescita Therapeutics Inc.
Via Business Wire
Crescita Therapeutics Announces Approval of Normal Course Issuer Bid
From Crescita Therapeutics
Via Business Wire
Crescita Reports Second Quarter 2023 Results
From Crescita Therapeutics
Via Business Wire
Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders
From Crescita Therapeutics
Via Business Wire
Crescita Reports First Quarter 2023 Results
From Crescita Therapeutics Inc.
Via Business Wire
Crescita Reports Q4 and Fiscal 2022 Results
From Crescita Therapeutics Inc.
Via Business Wire
Crescita Reports Third Quarter 2022 Results
From Crescita Therapeutics Inc.
Via Business Wire
Crescita Reports Second Quarter 2022 Results
From Crescita Therapeutics Inc.
Via Business Wire
Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders
From Crescita Therapeutics
Via Business Wire
Crescita Reports First Quarter 2022 Results
From Crescita Therapeutics
Via Business Wire
Crescita to Present at Bloom Burton & Co. Healthcare Investor Conference
From Crescita Therapeutics
Via Business Wire
Crescita Reports Q4 and Fiscal 2021 Results
From Crescita Therapeutics Inc.
Via Business Wire
Crescita Therapeutics Announces Renewal of Normal Course Issuer Bid
From Crescita Therapeutics
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.